Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

CJC-1295: Oral vs. Injectable – A 2026 Deep Dive

As we navigate 2026, the landscape of peptide research continues its remarkable, sometimes dramatic shift, demanding precision and innovation from every corner of the scientific community. Among the compounds commanding significant attention is CJC-1295, a syn

As we navigate 2026, the landscape of peptide research continues its remarkable, sometimes dramatic shift, demanding precision and innovation from every corner of the scientific community. Among the compounds commanding significant attention is CJC-1295, a synthetic analog of growth hormone-releasing hormone (GHRH). It's a fascinating molecule, isn't it? For those conducting advanced biological research, a critical decision often emerges: the optimal route of administration. Specifically, the debate around CJC-1295 oral vs injectable formulations is more relevant now than ever.

Here at Real Peptides, we've spent years observing, synthesizing, and understanding these intricate compounds. Our commitment to high-purity, research-grade peptides means we're constantly evaluating the best practices for their use in cutting-edge studies. That's why we're delving deep into the pivotal differences between CJC-1295 oral vs injectable methods, offering our collective expertise to help you make informed decisions for your vital work.

Unpacking CJC-1295: A Brief Overview

Before we dissect the delivery methods, let's briefly touch on what CJC-1295 actually is. It's a long-acting GHRH analog designed to stimulate the pituitary gland's natural production and secretion of growth hormone (GH). The 'DAC' (Drug Affinity Complex) modification, often associated with CJC-1295, extends its half-life, allowing for less frequent dosing. This mechanism is crucial for researchers exploring its potential in areas like muscle growth, recovery, fat metabolism, and even some aspects of cellular repair. Our team has found that understanding the fundamental action of the peptide is the first step in optimizing its research application, whether you're considering CJC-1295 oral vs injectable.

It's important to remember that we're talking about a compound that interacts directly with the body's intricate endocrine system. Precision, as you can imagine, is absolutely paramount. The integrity of the peptide itself—its purity and exact amino-acid sequencing—forms the bedrock of any meaningful research outcome. This is where Real Peptides truly shines; every peptide we offer, including CJC 1295 (no Dac) and the popular CJC-1295 + Ipamorelin (5mg/5mg) blend, is crafted through small-batch synthesis, guaranteeing the consistency and reliability your lab demands.

The Injectable Route: Precision, Bioavailability, and Established Protocols

When most researchers think about peptide administration, injections, typically subcutaneous, are what come to mind. And for good reason. The injectable route for CJC-1295 offers a direct, highly controlled method of introducing the compound into the systemic circulation. This bypasses the digestive system entirely, which is a significant advantage for peptide stability.

Superior Bioavailability: Honestly, this is the primary, non-negotiable benefit of injection. Peptides, by their very nature, are chains of amino acids. They're fragile. The hostile environment of the gastrointestinal tract, with its enzymes and varying pH levels, can quickly degrade these delicate structures. Injecting CJC-1295 ensures a much higher percentage of the active compound reaches the bloodstream intact, ready to exert its intended effect. Our experience shows this leads to more predictable and consistent research results, which is invaluable in scientific inquiry. When considering CJC-1295 oral vs injectable, bioavailability often tips the scales.

Established Research Protocols: The vast majority of historical and ongoing research into peptides like CJC-1295 has utilized injectable methods. This means there's a wealth of data, established dosing guidelines, and validated administration techniques to draw upon. Researchers can rely on a well-understood framework, reducing variables and enhancing the reproducibility of their studies. This isn't just convenience; it's a foundational element of sound scientific methodology.

Control Over Dosing: With injections, researchers have exquisite control over the exact dose administered. While reconstitution with Bacteriostatic Reconstitution Water (bac) requires careful measurement, once prepared, the delivered dose is precise. This accuracy is critical when you're trying to correlate specific peptide concentrations with physiological responses, especially in complex areas like Hormone & Gh Research.

Of course, there are practical considerations. Injectable administration requires sterile technique, proper needle disposal, and a willingness to self-administer (or have it administered). But for many researchers, these minor inconveniences are far outweighed by the benefits of precision and efficacy when evaluating CJC-1295 oral vs injectable methods.

The Oral Route: Convenience, Innovation, and Challenges

The idea of a simple pill for a peptide like CJC-1295 is undeniably appealing. Who wouldn't prefer that, right? The oral route offers unparalleled convenience, eliminating the need for needles, sterile preparation, and the logistical challenges sometimes associated with injectables. This ease of use could, theoretically, broaden the accessibility of peptide research.

Emerging Formulations: Historically, oral peptide delivery has been a formidable, often moving-target objective due to the aforementioned degradation issues. However, 2026 is seeing significant advancements in oral peptide technology. Companies are developing specialized enteric coatings, protease inhibitors, and advanced formulations designed to protect peptides from the harsh gastrointestinal environment and enhance their absorption. We've seen exciting developments in this space, even with other compounds, such as the innovative Orforglipron Tablets for metabolic research. These represent a promising future for oral peptide delivery.

Reduced Barrier to Entry: For certain types of research, particularly those involving less invasive methods or broader participant groups, an oral formulation could significantly lower the barrier to entry. No one loves needles, after all. This potential for greater comfort might lead to higher compliance in longer-term studies, which is a practical consideration for researchers.

The Bioavailability Hurdle: Here's the catch, though. Despite the advancements, achieving comparable bioavailability to injectable methods for most peptides orally remains a significant challenge. Even with protective measures, a substantial portion of the peptide can still be degraded or poorly absorbed. This often necessitates much higher oral doses to achieve the same systemic effect as a smaller injected dose. This is a critical factor when assessing CJC-1295 oral vs injectable approaches, impacting both cost-effectiveness and the interpretability of results.

Less Established Research: Compared to injectables, the body of scientific literature on oral CJC-1295 is considerably smaller. This means researchers often have fewer established benchmarks, validated dosing regimens, or long-term efficacy and safety data to rely upon. Conducting studies with oral formulations might require more foundational research to establish optimal parameters, adding layers of complexity to experimental design. This is a crucial distinction in the CJC-1295 oral vs injectable debate.

CJC-1295 Oral vs Injectable: A Head-to-Head Comparison

Let's be honest, this is where the rubber meets the road. When you're standing at the crossroads of experimental design, choosing between CJC-1295 oral vs injectable isn't just a matter of preference; it's a strategic decision that can profoundly influence your research outcomes. Our team consistently advises researchers to weigh these factors with meticulous care.

Bioavailability

High (near 100% for subcutaneous)

Lower (variable, subject to degradation and absorption)

Onset of Action

Rapid and predictable

Slower, potentially less predictable

Precision

High (exact dosing, direct systemic delivery)

Moderate (dose may need to be higher to compensate for loss)

Convenience

Lower (requires sterile technique, needles)

High (simple pill/liquid intake)

Stability

Excellent (reconstituted vial, kept refrigerated)

Challenging (susceptible to GI degradation, formulation dependent)

Research Data

Extensive, well-established protocols

Limited, emerging, less standardized

Cost (per effective dose)

Potentially lower due to higher bioavailability

Potentially higher due to lower bioavailability needing more material

Common Form

Lyophilized powder for reconstitution

Tablets or specialized liquid formulations

We can't stress this enough: the fundamental difference lies in how the peptide interacts with the body from the moment of administration. With an injectable, you're bypassing the first line of defense—the digestive system—and delivering the peptide directly into the bloodstream. This is a significant advantage for compounds like Tesamorelin 10mg or Ipamorelin as well, where systemic presence is critical for efficacy. When we consider CJC-1295 oral vs injectable, this bypass mechanism is often the deciding factor for robust studies.

The Purity Imperative: A Real Peptides Standard

Regardless of whether you choose CJC-1295 oral vs injectable for your research, one factor remains universally, critically important: the purity and quality of the peptide itself. A poorly synthesized or contaminated peptide can lead to inconsistent results, introduce unwanted variables, or even compromise the integrity of your entire study. This is a non-negotiable element of effective scientific inquiry.

Our team at Real Peptides understands this implicitly. We're not just suppliers; we're partners in discovery. That's why we adhere to stringent quality control measures, ensuring every batch of our research-grade peptides, from TB-500 (thymosin Beta-4) to Epithalon, meets the highest standards of purity and consistency. Our small-batch synthesis process with exact amino-acid sequencing guarantees you're getting precisely what you need for reliable, reproducible results. We believe this unwavering commitment to quality is what truly differentiates us in the biotechnology space. It's comprehensive.

When you're conducting Performance & Recovery Research or diving into Longevity Research, the foundation of your work is the quality of your materials. It's the same principle whether you're evaluating CJC-1295 oral vs injectable. You need to trust that the compound you're working with is exactly as specified, free from impurities that could skew your data or lead to erroneous conclusions. Our team is always ready to discuss our quality assurance processes and help you Find the Right Peptide Tools for Your Lab.

Practical Considerations for Your Research in 2026

Choosing between CJC-1295 oral vs injectable isn't a simple yes or no; it's a nuanced decision driven by your specific research objectives, experimental design, and logistical capabilities. Here's what we recommend considering:

Research Goals: Are you aiming for maximal, predictable physiological response (e.g., in a controlled animal study)? Or are you exploring broader accessibility or patient compliance in a less acute setting? Your goals dictate the route.

Data Reliability: For studies requiring high precision and direct correlation between dose and effect, the injectable route often provides more reliable data due to superior bioavailability and established protocols. It's just a fact.

Ethical and Practical Considerations: If your study involves a larger cohort where ease of administration is paramount, and you're willing to account for potentially lower or more variable bioavailability, an oral formulation might be explored. But ensure you have robust methods for assessing actual systemic exposure.

Cost-Benefit Analysis: While oral formulations might seem cheaper per unit, the need for higher doses to achieve equivalent systemic exposure can sometimes make them more expensive in the long run. Calculate the 'effective dose' cost when comparing CJC-1295 oral vs injectable.

Availability of Specific Formulations: As of 2026, high-purity injectable CJC-1295 is widely available from reputable suppliers like Real Peptides. Oral formulations are still an area of active development and research for many peptides, so availability and consistency can vary.

We encourage researchers to engage with us. Our expertise extends beyond simply supplying peptides; we're here to offer insights into their optimal use. Whether you're researching Muscle Building Research or exploring Metabolic & Weight Research, the right delivery method is a critical component of success. It really is.

The Future of Peptide Delivery: Beyond CJC-1295 Oral vs Injectable

The scientific community's relentless pursuit of innovation means the discussion around CJC-1295 oral vs injectable is just one chapter in a much larger story. Researchers are continually exploring novel delivery systems that could revolutionize how peptides are administered. Think transdermal patches, nasal sprays, or even implantable devices that offer sustained release. These aren't just theoretical musings; some are already in advanced stages of development for various therapeutic peptides. It's exciting, to say the least.

For example, while we've seen promising oral advancements with compounds like SLU-PP-332 Capsules (sloop), the challenge of systemic absorption for complex peptides remains. The goal is always to maximize efficacy while minimizing invasiveness and side effects. As these technologies mature, they could offer even more nuanced choices for researchers, further complicating (or simplifying, depending on your perspective) the decision-making process. But for now, the CJC-1295 oral vs injectable debate remains central.

Our team at Real Peptides is always monitoring these developments, ensuring that our product offerings and insights remain at the forefront of peptide research. We’re dedicated to supporting your cutting-edge work, providing the highest quality research materials, and sharing our deep industry expertise. We invite you to explore our full range of peptides and discover how our commitment to purity can elevate your research standards. That's the key.

The choice between CJC-1295 oral vs injectable is a significant one, underscoring the complexities inherent in modern biological research. It demands a thorough understanding of pharmacokinetics, bioavailability, and the specific requirements of your experimental design. Our collective experience shows that while convenience is tempting, the pursuit of scientific rigor often necessitates the most direct and predictable route. For critical research, prioritizing the established efficacy and consistency of injectable CJC-1295 often provides the most robust results. However, we're not dismissing the promising future of oral formulations; they're certainly on our radar. Ultimately, your research deserves the highest quality inputs and the most thoughtful approach to administration. We're here to help you achieve exactly that.

Frequently Asked Questions

The primary difference lies in bioavailability and degradation. Injectable forms (typically subcutaneous) deliver the peptide directly into the bloodstream, bypassing the harsh digestive system, thus ensuring higher bioavailability and less degradation. Oral forms must survive the stomach’s acidic environment and enzymatic breakdown, leading to lower and more variable absorption.

Injectable administration of CJC-1295 generally offers significantly better bioavailability. This means a larger percentage of the active peptide reaches systemic circulation, leading to more predictable and consistent effects for research purposes. Oral forms usually require much higher doses to achieve comparable systemic exposure.

While injectable CJC-1295 is a well-established research compound, oral formulations are still an area of active development and research for many peptides, including CJC-1295. Some experimental oral forms might exist, but they are generally less common and less validated than injectables in 2026. Researchers often look to advancements in oral delivery for other peptides, like [Orforglipron Tablets](https://www.realpeptides.co/products/orforglipron-peptide-tablets/), as indicators of future possibilities.

The oral route offers superior convenience, eliminating the need for needles, sterile preparation, and proper disposal. This can be a significant advantage for long-term studies or those with broader participant groups. Injectable administration requires more careful handling and adherence to sterile techniques, though its benefits often outweigh this for precise research.

No, the purity of CJC-1295 is paramount regardless of the administration route. Impurities can compromise research results and introduce unwanted variables, whether the compound is injected or taken orally. At Real Peptides, we emphasize high-purity, exact amino-acid sequencing for all our research peptides to ensure reliable data.

For injectable CJC-1295, dosing is typically precise due to high bioavailability. With oral forms, researchers often need to account for significant degradation and incomplete absorption, meaning a much higher initial dose may be required to achieve an equivalent systemic concentration. This difference in effective dosing is a critical aspect of the CJC-1295 oral vs injectable debate.

The injectable route, particularly subcutaneous injection, has a far more established history of research protocols for CJC-1295. The vast majority of scientific literature and clinical studies have utilized this method, providing a robust foundation for researchers to build upon. Oral forms, while innovative, have less historical data to guide their use.

While significant advancements in oral peptide delivery are ongoing in 2026, making it ‘as effective’ as injectable CJC-1295 in terms of bioavailability and predictable systemic delivery remains a formidable challenge. Researchers are exploring various protective formulations, but injectables still hold a distinct advantage for direct and unhindered peptide action.

Yes, generally it does. Injectable CJC-1295 typically has a more rapid and predictable onset of action because it’s quickly absorbed into the bloodstream. Oral formulations, due to the processes of digestion and absorption, tend to have a slower and potentially less predictable onset, depending on the specific formulation and individual physiology.

Research focusing on long-term compliance, ease of administration in broader participant groups, or exploring novel peptide delivery systems might favor oral CJC-1295, assuming effective formulations become widely available. However, for studies requiring precise dosing and maximal efficacy, injectable forms usually remain the preferred choice.

At Real Peptides, our quality assurance processes are rigorous for all compounds. We focus on small-batch synthesis with exact amino-acid sequencing, ensuring high purity and consistency. This commitment applies whether we’re providing injectable lyophilized powder like [CJC 1295 (no Dac)](https://www.realpeptides.co/products/cjc-1295-no-dac/) or if future oral formulations were to meet our stringent standards.

Injectable administration carries risks associated with injections, such as site reactions or infection if proper sterile technique isn’t followed. Oral administration, while avoiding needles, might introduce concerns related to gastrointestinal upset, unknown interactions with other oral compounds, or the safety profile of novel excipients used in oral formulations. Always consult current research and guidelines.

Injectable CJC-1295, typically stored as a lyophilized powder and reconstituted with [Bacteriostatic Reconstitution Water (bac)](https://www.realpeptides.co/products/bacteriostatic-water/), offers excellent stability when stored correctly. Oral forms face challenges with chemical stability in the digestive tract, requiring advanced encapsulation or formulation techniques to protect the peptide, which can vary widely in effectiveness.

You can find high-purity, research-grade CJC-1295, including compounds like [CJC-1295 + Ipamorelin (5mg/5mg)](https://www.realpeptides.co/products/cjc1295-ipamorelin-5mg-5mg/), on our website, Real Peptides. We specialize in providing meticulously synthesized peptides that meet the stringent demands of cutting-edge biological research. Our team ensures every product supports reliable and reproducible study outcomes.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosing Protocols and Administration Timing for CJC-1295

Research-grade CJC-1295 dosing in human trials has ranged from 30mcg/kg to 60mcg/kg administered subcutaneously once weekly. For a 75kg individual, this translates to approximately 2.25mg per injection. The dose-response curve shows diminishing returns above 60mcg/kg. Higher doses produce marginal additional IGF-1 elevation but increase the incidence of transient side effects like injection site reactions and mild water retention. Most published recomposition protocols use the lower end (30–45mcg/kg weekly) to balance efficacy with tolerability. Timing relative to training and feeding windows is frequently debated but lacks strong empirical support. CJC-1295's extended half-life means plasma concentrations remain relatively stable across the week. There is no acute post-injection GH spike that benefits from specific nutrient timing. Some researchers prefer evening administration to align with natural nocturnal GH pulses, but controlled trials show no significant difference in IGF-1 response between morning and evening dosing. Consistency matters more than timing. Reconstitution requires bacteriostatic water at a 1:1 or 2:1 ratio (2mg peptide in 1–2mL water), with the solution refrigerated at 2–8°C and used within 28 days. Lyophilised powder should be stored at −20°C before reconstitution. Temperature excursions above 8°C after mixing cause irreversible protein denaturation. A single overnight mistake renders the peptide inactive, though visual inspection won't reveal degrada…
STORAGE

Reconstitution and Storage: Essential Steps for Researchers

Handling peptides correctly after they arrive is absolutely critical for maintaining their stability and efficacy. We've seen promising research derailed by improper reconstitution or storage, and it's a frustrating, preventable setback. For any CJC-1295 beginners guide, this section is indispensable. When you receive your lyophilized (freeze-dried) CJC-1295, it's a stable powder. However, once you reconstitute it, things change. Reconstitution typically involves mixing the peptide powder with a sterile diluent, most commonly Bacteriostatic Reconstitution Water (bac). It's crucial to use the correct amount of diluent to achieve your desired concentration, and to do so gently. We recommend slowly adding the water down the side of the vial, then allowing it to dissolve naturally without vigorous shaking, which can degrade the peptide structure. This approach (which we've refined over years) delivers real results. Once reconstituted, CJC-1295 becomes much more fragile. It must be stored refrigerated, typically at 2-8°C (36-46°F), and kept away from light. Freezing can sometimes extend its lifespan further, but repeated freeze-thaw cycles are generally detrimental. Our team advises researchers to reconstitute only what they need for a specific period and to discard any unused portions after a recommended timeframe, usually a few weeks to a month, depending on the specific peptide and storage conditions. This meticulous approach ensures the integrity of your research material, ma…
02

Question drills

Open a question for its connected answer.

01What If IGF-1 Increases Less Than 20ng/mL After 8 Weeks on the Standard 50+ Protocol?+

Increase the GHRP dose to 250–300mcg per administration while keeping CJC-1295 at 200mcg twice weekly. If IGF-1 remains unchanged after another 4 weeks, the limitation is likely hepatic, not pituitary. Order a metabolic panel (fasting glucose, HbA1c, liver enzymes) and assess for insulin resistance or hepatic steatosis. Correcting the metabolic substrate through dietary intervention or metformin often restores IGF-1 responsiveness within 6 weeks. Increasing CJC-1295 dose beyond 200mcg twice-weekly in confirmed non-responders achieves nothing except higher peptide waste.

SOURCE / realpeptides.co ↗
02What If I Accidentally Reconstituted a 2mg Vial with 4mL Instead of 2mL?+

You now have 0.5mg/mL instead of 1mg/mL. The peptide is still usable, but every dose requires double the injection volume. If your protocol calls for 200μg, you'll need to inject 400μL instead of 200μL. The peptide won't degrade faster at this lower concentration, but the larger volume increases injection discomfort and requires a larger syringe. You can't 'fix' this by evaporating water. That would concentrate contaminants and destabilise the peptide. Use the batch as-is and adjust your dosing calculations, or discard it and reconstitute a new vial correctly.

SOURCE / realpeptides.co ↗
03What If CJC-1295 DAC and No-DAC Are Mixed in the Same Syringe?+

Do not mix variants. CJC-1295 DAC and no-DAC have different pharmacokinetic profiles. Combining them creates unpredictable plasma concentration curves that confound research data. The DAC variant's albumin binding does not interfere with the no-DAC variant's receptor activity, but the resulting GH secretion pattern becomes uninterpretable. Use separate administration schedules if both are part of a protocol.

SOURCE / realpeptides.co ↗
04What If a Research Subject Uses CJC-1295 Without Adjusting Caloric Intake?+

Expect elevated serum GH and free fatty acids with minimal fat mass reduction. Growth hormone increases lipolysis, but without increased oxidative demand or reduced intake, released fatty acids recirculate and re-store. A 2021 pilot study found subjects using CJC-1295 ad libitum (no dietary restriction) showed no significant body composition changes over 8 weeks despite 240% higher mean GH levels. The peptide creates metabolic flexibility but doesn't force substrate utilization. Protocols designed to study fat loss must include structured caloric prescription. CJC-1295 enhances outcomes within deficit states, it doesn't replace them.

SOURCE / realpeptides.co ↗
05What if I miss a scheduled CJC-1295 dose by several days?+

Administer the missed dose as soon as you remember and resume your regular schedule. Because CJC-1295 has a half-life of 6–8 days, missing a dose by 2–3 days still leaves residual peptide in circulation. GH pulses may decrease in amplitude but do not cease entirely. Do not double-dose to compensate. Pharmacokinetic data from Phase I trials show that doses above 120 mcg/kg do not produce proportionally greater GH response and increase the likelihood of injection site reactions.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Evolving Understanding and Research Applications

Over the past decade, our understanding of CJC-1295's nuances has deepened considerably. Researchers have explored its synergistic effects when combined with other growth hormone secretagogues, such as Ipamorelin. The combination of CJC-1295 + Ipamorelin (5mg/5mg) has become a popular research protocol, as Ipamorelin, a selective GHRP (Growth Hormone-Releasing Peptide), works through a different mechanism (stimulating ghrelin receptors) to further enhance GH pulsatility. This dual-action approach often yields more robust and physiologically balanced GH release, which is why we often see it requested for Performance & Recovery Research and even aspects of Longevity Research. The applications of CJC-1295 have also diversified. Beyond its initial focus on age-related GH decline and body composition, research has delved into its potential roles in promoting tissue repair, improving sleep quality, and even enhancing cognitive function indirectly through its systemic effects. The breadth of its investigative uses speaks volumes about its versatility within the peptide research community. We’ve seen researchers explore its utility in contexts ranging from recovery protocols to metabolic health, underscoring its broad biological impact. This expanded scope is a critical chapter in the ongoing CJC-1295 history.

RESEARCH

Navigating the Landscape of Peptide Research in 2026

As we look ahead to the rest of 2026, the field of peptide research continues its rapid expansion. New applications are constantly emerging, from advancements in Cognitive & Nootropic Research to exciting breakthroughs in Longevity Research. With this increased complexity comes an even greater need for stringent quality control and a thorough understanding of peptide stability. The challenge of CJC-1295 degradation reconstituted isn't going away; if anything, it becomes more pronounced as researchers push the boundaries of what's possible. This is where the expertise of a dedicated supplier truly shines. Our team is constantly monitoring the latest research, refining our synthesis processes, and enhancing our quality assurance protocols to stay ahead of the curve. We mean this sincerely: it runs on genuine connections and a shared dedication to scientific excellence. By choosing a partner like Real Peptides, you're not just getting a product; you're gaining access to a wealth of knowledge and a steadfast commitment to helping you achieve reproducible, impactful results. We invite you to explore our full range and see the difference that true dedication to purity makes.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

Comparison: GHRH Analogues and Growth Hormone Secretagogues

Understanding the landscape of compounds that influence growth hormone release is crucial for any researcher. While CJC-1295 for growth hormone release is a star player, it's part…

Comparison

Identifying the Real Deal: Our Expert Checklist for CJC-1295 Quality Real vs Fake

So, how do you actually tell the difference? Our team has developed a comprehensive approach over years of industry experience. It's a multi-faceted process, certainly not a singl…

Comparison

Clinical Comparison: CJC-1295 DAC vs Modified GHRH Without DAC

The development of CJC-1295 spawned a related peptide variant commonly referred to as "Modified GRF(1-29)" or "CJC-1295 without DAC," which contains the same four amino acid subst…